Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Budi Riyanto Wreksoatmodjo
Fakultas Kedokteran dan Ilmu Kesehatan Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Sindrom Guillain-Barre sebagai Gejala COVID-19 dan Potensi Efek Samping Pasca-Vaksinasi COVID-19 Joanesa Della Felista; Budi Riyanto Wreksoatmodjo
Cermin Dunia Kedokteran Vol. 49 No. 9 (2022): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i9.295

Abstract

COVID-19 adalah penyakit infeksi virus SARS-CoV-2. Gejala umum COVID-19 adalah pada saluran pernapasan, namun dapat ditemukan gejala neurologis antara lain sindrom Guillain-Barré (GBS). Hingga saat ini prevalensi kasus GBS pada pasien COVID-19 sekitar 0,15%. Selain itu, GBS juga dapat merupakan salah satu efek samping setelah pemberian vaksin COVID-19. Insiden GBS lebih banyak pada penerima vaksin viral vector (0,38/100.000 dosis) dibandingkan penerima vaksin mRNA (0,18/100.000 dosis). Hingga saat ini belum ada laporan kasus GBS pasca-vaksinasi berbasis protein. Hampir semua kasus GBS baik yang menerima vaksin berbasis mRNA maupun viral vector menunjukkan respons baik terhadap terapi IVIg.   COVID 19 is primarily a respiratory viral infection, but there are reports of neurological symptoms among patients; one of the accompanying neurological symptoms is Guillain-Barré Syndrome (GBS). Its prevalence among COVID 19 patients is approximately 0.15%. GBS is also reported as a side effect after COVID vaccinations. Its incidence in greater among viral vector vaccine recipients (0.38/100.000 doses) as compared to mRNA vaccine recipients (0.18/ 100.000 doses). No GBS case was reported after protein-based vaccine administration. The majority of cases responded well after IVIg therapy.
Sindrom Guillain-Barre sebagai Gejala COVID-19 dan Potensi Efek Samping Pasca-Vaksinasi COVID-19 Joanesa Della Felista; Budi Riyanto Wreksoatmodjo
Cermin Dunia Kedokteran Vol 49 No 9 (2022): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v49i9.295

Abstract

COVID-19 adalah penyakit infeksi virus SARS-CoV-2. Gejala umum COVID-19 adalah pada saluran pernapasan, namun dapat ditemukan gejala neurologis antara lain sindrom Guillain-Barré (GBS). Hingga saat ini prevalensi kasus GBS pada pasien COVID-19 sekitar 0,15%. Selain itu, GBS juga dapat merupakan salah satu efek samping setelah pemberian vaksin COVID-19. Insiden GBS lebih banyak pada penerima vaksin viral vector (0,38/100.000 dosis) dibandingkan penerima vaksin mRNA (0,18/100.000 dosis). Hingga saat ini belum ada laporan kasus GBS pasca-vaksinasi berbasis protein. Hampir semua kasus GBS baik yang menerima vaksin berbasis mRNA maupun viral vector menunjukkan respons baik terhadap terapi IVIg.   COVID 19 is primarily a respiratory viral infection, but there are reports of neurological symptoms among patients; one of the accompanying neurological symptoms is Guillain-Barré Syndrome (GBS). Its prevalence among COVID 19 patients is approximately 0.15%. GBS is also reported as a side effect after COVID vaccinations. Its incidence in greater among viral vector vaccine recipients (0.38/100.000 doses) as compared to mRNA vaccine recipients (0.18/ 100.000 doses). No GBS case was reported after protein-based vaccine administration. The majority of cases responded well after IVIg therapy.
Co-Authors Joanesa Della Felista